To investigate the effects of docetaxel combined with cisplatin on survival time of non-small cell lung cancer (NSCLC), and its influence on patient’s survival time.

Ninety-four patients with advanced NSCLC treated in the First Affiliated Hospital of Zhengzhou University from August 2017 to August 2018 were enrolled and divided into control group and observation group by random number table method, with 47 cases in each group. Patients in the control group received the docetaxel; while observation group received the cisplatin and docetaxel. The clinical efficacy, survival time, levels of serum tumor markers, quality of life and adverse reactions were compared between the two groups.

The overall disease remission rate of the observation group was 34.04%(16/47), higher than the 21.28% (10/47) of the control group; while the overall disease control rate in the observation group was 78.72% (37/47), higher than the 63.83% (30/47) in the control group, and the difference was not significant (P>0.05). The median survival and progression-free survival of the observation group were significantly longer than those of the control group (P<0.05). The levels of carcinoembryonic antigen and thymidine kinase-1 in the observation group were lower than those in the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The quality of life score in the observation group was higher than that in the control group (P<0.05).

Docetaxel combined with cisplatin has a good therapeutic effect on NSCLC patients, which can significantly reduce the levels of serum tumor markers, prolong survival time and improve quality of life, to which the patients have a good tolerance.

Cacimoma, non-small cell lung; Docetaxel; Cisplatin; Survival time